vs

Side-by-side financial comparison of ALASKA AIR GROUP, INC. (ALK) and Becton Dickinson (BDX). Click either name above to swap in a different company.

Becton Dickinson is the larger business by last-quarter revenue ($5.3B vs $3.3B, roughly 1.6× ALASKA AIR GROUP, INC.). Becton Dickinson runs the higher net margin — 7.3% vs -5.8%, a 13.1% gap on every dollar of revenue. On growth, ALASKA AIR GROUP, INC. posted the faster year-over-year revenue change (5.2% vs -0.4%). Over the past eight quarters, ALASKA AIR GROUP, INC.'s revenue compounded faster (6.7% CAGR vs 2.0%).

Alaska Air Group, Inc. is an American airline holding company based in SeaTac, Washington, United States. The group owns two mainline carriers, Alaska Airlines and Hawaiian Airlines, along with a regional airline, Horizon Air. Alaska Airlines in turn wholly owns an aircraft ground handling company, McGee Air Services.

Becton, Dickinson and Company is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.

ALK vs BDX — Head-to-Head

Bigger by revenue
BDX
BDX
1.6× larger
BDX
$5.3B
$3.3B
ALK
Growing faster (revenue YoY)
ALK
ALK
+5.6% gap
ALK
5.2%
-0.4%
BDX
Higher net margin
BDX
BDX
13.1% more per $
BDX
7.3%
-5.8%
ALK
Faster 2-yr revenue CAGR
ALK
ALK
Annualised
ALK
6.7%
2.0%
BDX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
ALK
ALK
BDX
BDX
Revenue
$3.3B
$5.3B
Net Profit
$-193.0M
$382.0M
Gross Margin
45.9%
Operating Margin
-8.5%
10.5%
Net Margin
-5.8%
7.3%
Revenue YoY
5.2%
-0.4%
Net Profit YoY
24.0%
EPS (diluted)
$-1.69
$1.34

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALK
ALK
BDX
BDX
Q1 26
$3.3B
Q4 25
$3.6B
$5.3B
Q3 25
$3.8B
$5.9B
Q2 25
$3.7B
$5.5B
Q1 25
$3.1B
$5.3B
Q4 24
$3.5B
$5.2B
Q3 24
$3.1B
$5.4B
Q2 24
$2.9B
$5.0B
Net Profit
ALK
ALK
BDX
BDX
Q1 26
$-193.0M
Q4 25
$21.0M
$382.0M
Q3 25
$73.0M
$493.0M
Q2 25
$172.0M
$574.0M
Q1 25
$-166.0M
$308.0M
Q4 24
$71.0M
$303.0M
Q3 24
$236.0M
$400.0M
Q2 24
$220.0M
$487.0M
Gross Margin
ALK
ALK
BDX
BDX
Q1 26
Q4 25
45.9%
Q3 25
47.5%
Q2 25
47.8%
Q1 25
42.8%
Q4 24
43.2%
Q3 24
45.7%
Q2 24
46.2%
Operating Margin
ALK
ALK
BDX
BDX
Q1 26
-8.5%
Q4 25
2.1%
10.5%
Q3 25
3.9%
11.8%
Q2 25
7.5%
16.0%
Q1 25
-6.3%
10.4%
Q4 24
2.1%
8.8%
Q3 24
11.1%
11.4%
Q2 24
11.1%
12.1%
Net Margin
ALK
ALK
BDX
BDX
Q1 26
-5.8%
Q4 25
0.6%
7.3%
Q3 25
1.9%
8.4%
Q2 25
4.6%
10.4%
Q1 25
-5.3%
5.8%
Q4 24
2.0%
5.9%
Q3 24
7.7%
7.4%
Q2 24
7.6%
9.8%
EPS (diluted)
ALK
ALK
BDX
BDX
Q1 26
$-1.69
Q4 25
$0.14
$1.34
Q3 25
$0.62
$1.71
Q2 25
$1.42
$2.00
Q1 25
$-1.35
$1.07
Q4 24
$0.58
$1.04
Q3 24
$1.84
$1.37
Q2 24
$1.71
$1.68

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALK
ALK
BDX
BDX
Cash + ST InvestmentsLiquidity on hand
$451.0M
$740.0M
Total DebtLower is stronger
$5.3B
Stockholders' EquityBook value
$3.7B
$25.3B
Total Assets
$20.3B
$54.8B
Debt / EquityLower = less leverage
1.43×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALK
ALK
BDX
BDX
Q1 26
$451.0M
Q4 25
$627.0M
$740.0M
Q3 25
$2.3B
$641.0M
Q2 25
$2.1B
$735.0M
Q1 25
$2.5B
$667.0M
Q4 24
$2.5B
$711.0M
Q3 24
$2.5B
$1.7B
Q2 24
$2.5B
$4.5B
Total Debt
ALK
ALK
BDX
BDX
Q1 26
$5.3B
Q4 25
$4.8B
Q3 25
$5.0B
Q2 25
$4.9B
Q1 25
$4.8B
Q4 24
$4.5B
Q3 24
$4.6B
Q2 24
$2.7B
Stockholders' Equity
ALK
ALK
BDX
BDX
Q1 26
$3.7B
Q4 25
$4.1B
$25.3B
Q3 25
$4.0B
$25.4B
Q2 25
$3.9B
$25.5B
Q1 25
$4.1B
$25.2B
Q4 24
$4.4B
$25.2B
Q3 24
$4.5B
$25.9B
Q2 24
$4.2B
$25.9B
Total Assets
ALK
ALK
BDX
BDX
Q1 26
$20.3B
Q4 25
$20.4B
$54.8B
Q3 25
$20.0B
$55.3B
Q2 25
$19.9B
$54.9B
Q1 25
$19.8B
$54.5B
Q4 24
$19.8B
$54.7B
Q3 24
$19.6B
$57.3B
Q2 24
$15.3B
$55.6B
Debt / Equity
ALK
ALK
BDX
BDX
Q1 26
1.43×
Q4 25
1.17×
Q3 25
1.24×
Q2 25
1.26×
Q1 25
1.16×
Q4 24
1.04×
Q3 24
1.03×
Q2 24
0.63×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALK
ALK
BDX
BDX
Operating Cash FlowLast quarter
$229.0M
$657.0M
Free Cash FlowOCF − Capex
$549.0M
FCF MarginFCF / Revenue
10.5%
Capex IntensityCapex / Revenue
10.2%
2.1%
Cash ConversionOCF / Net Profit
1.72×
TTM Free Cash FlowTrailing 4 quarters
$2.6B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALK
ALK
BDX
BDX
Q1 26
$229.0M
Q4 25
$185.0M
$657.0M
Q3 25
$229.0M
$1.4B
Q2 25
$376.0M
$1.2B
Q1 25
$459.0M
$164.0M
Q4 24
$274.0M
$693.0M
Q3 24
$318.0M
$1.2B
Q2 24
$580.0M
$1.3B
Free Cash Flow
ALK
ALK
BDX
BDX
Q1 26
Q4 25
$549.0M
Q3 25
$1.0B
Q2 25
$1.0B
Q1 25
$35.0M
Q4 24
$588.0M
Q3 24
$882.0M
Q2 24
$1.1B
FCF Margin
ALK
ALK
BDX
BDX
Q1 26
Q4 25
10.5%
Q3 25
17.0%
Q2 25
19.0%
Q1 25
0.7%
Q4 24
11.4%
Q3 24
16.2%
Q2 24
22.4%
Capex Intensity
ALK
ALK
BDX
BDX
Q1 26
10.2%
Q4 25
2.1%
Q3 25
6.0%
Q2 25
3.2%
Q1 25
2.4%
Q4 24
2.0%
Q3 24
5.4%
Q2 24
3.6%
Cash Conversion
ALK
ALK
BDX
BDX
Q1 26
Q4 25
8.81×
1.72×
Q3 25
3.14×
2.75×
Q2 25
2.19×
2.12×
Q1 25
0.53×
Q4 24
3.86×
2.29×
Q3 24
1.35×
2.94×
Q2 24
2.64×
2.66×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALK
ALK

Passenger revenue$2.9B88%
Loyalty program other revenue$227.0M7%
Cargo and other revenue$153.0M5%

BDX
BDX

Other$2.8B53%
Medication Management Solutions$678.0M13%
Urologyand Critical Care$339.0M6%
Surgery$310.0M6%
Peripheral Intervention$265.0M5%
Specimen Management$245.0M5%
Advanced Patient Monitoring$178.0M3%
Diagnostic Solutions$176.0M3%
Bio Pharma Systems$150.0M3%
Biosciences$124.0M2%

Related Comparisons